Remove clinical shingles
article thumbnail

The Stages of Shingles

Drug Topics

The clinical manifestations of shingles can be divided into 3 phases.

187
187
article thumbnail

What side effects to expect from the shingles vaccine

The Checkup by Singlecare

Around the time you turn 50, you’ll need to step up your healthcare routine to avoid things like shingles, a painful infection that causes a viral rash. Luckily, there’s a shot to help prevent it: Shingrix, the shingles vaccine. As you prepare for your shot, here’s what you need to know about the side effects of the shingles vaccine.

Vaccines 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Shingles vaccine offers a decade of protection in older adults

European Pharmaceutical Review

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. Shingles occurs when the varicella zoster virus (VZV) is reactivated in a patient.

article thumbnail

Look out GSK, Pfizer and BioNTech are coming for Shingrix

pharmaphorum

GlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. billion in 2020 from its first indication of preventing shingles in the over-50s age group. Shingles is caused by the herpes zoster virus which also causes chickenpox.

Vaccines 104
article thumbnail

BioNTech targets infectious diseases for vaccine development

Pharmaceutical Technology

In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets. In December 2022, BioNTech initiated a Phase I clinical trial of BNT163 – an HSV vaccine candidate. In February 2023, BioNTech and Pfizer initiated a Phase I/II clinical trial in its shingles programme.

Vaccines 110
article thumbnail

L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

Pharmaceutical Technology

L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).

40
article thumbnail

VTP-400 by Barinthus Biotherapeutics for Herpes Zoster (Shingles): Likelihood of Approval

Pharmaceutical Technology

VTP-400 is under clinical development by Barinthus Biotherapeutics and currently in Phase I for Herpes Zoster (Shingles).

40